These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


118 related items for PubMed ID: 6217352

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Complete regression of skeletal metastases from hypernephroma after angioinfarction and medroxyprogesterone acetate therapy.
    Amin R.
    Urology; 1988 Sep; 32(3):254-8. PubMed ID: 2970709
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology.
    Damber JE, Bergh A, Landström M, Tomić R.
    J Urol; 1991 Jun; 145(6):1283-7. PubMed ID: 1827847
    [Abstract] [Full Text] [Related]

  • 31. [Clinovir treatment of adenocarcinoma of the uterus with lung metastases].
    Stertmann WA, Hocke M, Röttger P.
    MMW Munch Med Wochenschr; 1983 Jul 22; 125(29-30):685-6. PubMed ID: 6225946
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].
    Possinger K, Wagner H, Langecker P, Schmid L, Willich S, Wilmanns W.
    Fortschr Med; 1987 Jul 30; 105(22):421-4. PubMed ID: 2958397
    [No Abstract] [Full Text] [Related]

  • 34. Nuclear androgen receptor as marker of responsiveness to medroxyprogesterone acetate in human renal cell carcinoma.
    Concolino G, Marocchi A, Toscano V, Di Silverio F.
    J Steroid Biochem; 1981 Dec 30; 15():397-402. PubMed ID: 6461800
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The Cushing syndrome induced by medroxyprogesterone acetate.
    Siminoski K, Goss P, Drucker DJ.
    Ann Intern Med; 1989 Nov 01; 111(9):758-60. PubMed ID: 2552887
    [No Abstract] [Full Text] [Related]

  • 37. Scintigraphic evidence for the regression of skeletal metastases from a hypernephroma following long-term treatment with medroxyprogesterone acetate.
    Minervini R, Fiorentini L, Carlino F, Mazzuca N, Mariani G.
    J Nucl Med Allied Sci; 1982 Nov 01; 26(1):55-9. PubMed ID: 6213743
    [No Abstract] [Full Text] [Related]

  • 38. Experience with hormone receptors in renal cancer.
    Romics I, Rüssel C, Bach D.
    Int Urol Nephrol; 1990 Nov 01; 22(6):507-12. PubMed ID: 1965539
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 6.